Jan 13, 2020 — TUCSON, Ariz., Jan. 13, 2020 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter and year ending December 31, 2019. Highlights for the fourth quarter and full-year 2019 are presented below. 2019 Fourth Quarter and Full-Year Financial Highlights Commercially contracted instruments were 137 in the fourth quarter and 304 […]
Oct 03, 2019 — From IDWeek™, the annual meeting of the Infectious Diseases Society of America (IDSA) held in Washington, DC October 2 – 6. TUCSON, Ariz., Oct. 3, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced presentation of full data from three outcome studies at IDWeek™ 2019. The full data being presented build upon the high-level findings that […]
Sep 18, 2019 — Accelerate Diagnostics, Inc. recently highlighted the release of positive results from three clinical studies on the Accelerate Pheno™ system that will be presented at IDWeek™ 2019. “We are thrilled with the results of these clinical studies, which provide further evidence of the clinical value of Pheno,” commented Dr. Romney Humphries, Chief Scientific Officer of […]
Aug 02, 2019 — Today we announced the release and CE marking of our latest Accelerate PhenoTest™ BC kit, declaring conformity to the European Directive 98/79/EC on in vitro diagnostic medical devices. The new CE-IVD Accelerate PhenoTest™ BC kit now includes phenotypic antimicrobial susceptibility test (AST) results for ceftazidime-avibactam and ceftolozane-tazobactam for Enterobacteriaceae and P. aeruginosa bacteria, and trimethoprim-sulfamethoxazole […]
Jan 16, 2019 — University of Iowa Hospitals & Clinics, USA recently shared their adoption of the Accelerate Pheno™ system as a “new technology that helps diagnose and treat sepsis—a potentially life-threatening infection in the blood—faster than ever before.” Get the full story from UI Health Care Quick story excerpt: “Every hour counts,” explains Bradley Ford, MD, PhD, medical […]
Jan 06, 2019 — Added 117 commercially contracted U.S. instruments in Q4, doubling the regional installed base TUCSON, Ariz., Jan. 6, 2019 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX), today announced preliminary financial results for the quarter ending December 31, 2018. The company reported a 127.2% increase in U.S. instruments placed under commercial contract during the fourth quarter, and […]
Aug 06, 2018 — Revenue up 142 Percent, Global install base up 25 Percent TUCSON, Ariz., Aug. 6, 2018 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending June 30, 2018. The company posted revenue of $1.7 million, up 142% from the prior year quarter, and reported a record number of new agreements signed in […]
Jun 06, 2018 — Accelerate Diagnostics, Inc. announced today it will host symposia on the clinical opportunities of integrating fast, phenotypic susceptibility testing into antimicrobial stewardship programs and its impact on the management of patients with bacteremia at the American Society of Microbiologist Microbe 2018 forum in Atlanta, Georgia.
May 10, 2018 — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending March 31, 2018. The company generated revenue of $801,000, up 51% from the prior year, and reported signed agreements for 345 instruments.
May 03, 2018 — Accelerate Diagnostics, Inc. announced today that performance data will be presented during the Association of Medical Microbiology and Infectious Disease Canada/Canadian Association for Clinical Microbiology and Infectious Disease 2018 congress in Vancouver, Canada, May 2-5 at the Sheraton Vancouver Wall Centre. See the company’s press release for additional details.